MHLW Panel to Discuss Keytruda on Sept. 9, Listing Expected as Early as November

A key drug review committee of the Ministry of Health, Labor and Welfare (MHLW) will review on September 9 whether to back approval of MSD’s anti-PD-1 antibody pembrolizumab, known as Keytruda overseas, which will pit itself against Ono Pharmaceutical’s archrival...read more